Xcopri (Cenobamate) Patent Expiration, LOE Window & CMS Spending

Xcopri (Cenobamate) by Sk Life Science: FDA Orange Book core substance LOE 2032-10-30 (last listed 2039-06-16), 0 AB generics, $316.0M 2024 CMS Part D & Medicaid spend, and $1,180 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSk Life Science
FDA Application & PathwayN212839 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-10-30
Last Listed Patent or Exclusivity Date2039-06-16
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$316.0M
2024 Medicare Part D Spend$164.7M
2024 Medicaid Spend$151.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,180 intro WAC)